Referencias
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693613/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885827/
https://www.ncbi.nlm.nih.gov/books/NBK44775/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870347/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586661/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825138/
https://www.scienceopen.com/document?vid=a44f904f-fdeb-4e2d-9b79-7a1d3b3d9bc8
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5158159/
https://www.medicalnewstoday.com/articles/322513#facts-and-myths
Barry MJ, Meleth S, Lee JY, et al; Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group: Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA 306(12):1344-1351, 2011. doi: 10.1001/jama.2011.1364.
Tacklind J, Macdonald R, Rutks I, et al: Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 12:CD001423, 2012. doi: 10.1002/14651858.CD001423.
Vela-Navarrete R, Alcaraz A, Rodriguez-Antolin A, et al: Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int 10.1111/bju.14362, 2018. doi: 10.1111/bju.14362.
Lapi F, Gallo E, Giocaliere E, et al: Acute liver damage due to Serenoa repens: a case report. Br J Clin Pharmacol 69(5):558-560, 2010. doi: 10.1111/j.1365-2125.2010.03618.x.
Wargo KA, Allman E, Ibrahim F: A possible case of saw palmetto-induced pancreatitis. South Med J 103(7):683-685, 2010. doi: 10.1097/SMJ.0b013e3181e1e3ee.
Izzo AA, Ernst E: Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69(13):1777-1798, 2009. doi: 10.2165/11317010-000000000-00000.
Loguercio C and Festi D: Silybin and the liver: From basic research to clinical practice. World J Gastroenterol 17(18):2288–2301, 2011. doi: 10.3748/wjg.v17.i18.2288.
Voroneanu L, Nistor I, Dumea R, et al: Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Res 2016:5147468, 2016. doi: 10.1155/2016/5147468.
Ward J, Kapadia K, Brush E, et al: Amatoxin poisoning: case reports and review of current therapies. J Emerg Med 44(1):116-121, 2013. doi: 10.1016/j.jemermed.2012.02.020.
Rambaldi A, Jacobs BP, Gluud C: Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev (4)CD003620, 2007. doi: 10.1002/14651858.CD003620.pub3.
Fried MW, Navarro VJ, Afdhal N, et al: Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 308(3):274-282, 2012. doi: 10.1001/jama.2012.8265.
Valenzuela A, Aspillaga M, Vial S, et al: Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med 55(5):420-422, 1989. doi: 10.1055/s-2006-962056.
Wu JW, Lin LC, Tsai TH: Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 121(2):185-193, 2009. doi: 10.1016/j.jep.2008.10.036.
Jalloh MA, Gregory PJ, Hein D, et al: Dietary supplement interactions with antiretrovirals: a systematic review. Int J STD AIDS 28(1):4-15, 2017. doi: 10.1177/0956462416671087.